financetom
Personal Finance
financetom
/
Personal Finance
/
Research Alert: CFRA Lowers Opinion On Shares Of Adss Of Iqiyi Inc. To Sell From Hold
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Research Alert: CFRA Lowers Opinion On Shares Of Adss Of Iqiyi Inc. To Sell From Hold
Aug 28, 2025 8:19 AM

10:50 AM EDT, 08/28/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

Our revised target of USD2 (from USD1.70), implies a semi-annual blended P/E of 15.3x (vs. over 45x for its direct competitor Netflix and 30x for Bilibili), reflecting deteriorating margin prospects, macroeconomic uncertainties, and regulatory headwinds. We project revenue to decline 2% in 2025 before a modest 1% recovery in 2026, constrained by weaker content slates, tighter regulation on short dramas, and subdued ad spending in China amid macroeconomic uncertainty. Cost-cutting initiatives will constrain the release of premium content, weakening user engagement and advertising appeal, while intense competition with dominant players in China like Tencent Video and Kuaishou will hinder market share gains in the short drama market. Net margin is projected to contract further to 1.3% in 2025 from 2.6% in 2024, due to monetization challenges and elevated cost pressures, in our view. We cut our EPADS forecast to CNY0.38 from CNY1.07 for 2025 and to CNY1.06 from CNY1.38 for 2026, following disappointing Q2 results.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Research Alert: CFRA Raises Opinion On Shares Of Johnson & Johnson To Buy From Hold
Research Alert: CFRA Raises Opinion On Shares Of Johnson & Johnson To Buy From Hold
Oct 14, 2025
11:05 AM EDT, 10/14/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: After Q3 earnings and the announcement of the separation of Orthopedics, we raise our target to $220 from $166. This is based on 19.2x our 2026 EPS estimate and is...
Research Alert: CFRA Keeps Hold Opinion On Class B Shares Of Berkshire Hathaway Inc.
Research Alert: CFRA Keeps Hold Opinion On Class B Shares Of Berkshire Hathaway Inc.
Oct 12, 2025
01:00 AM EDT, 10/13/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We raise our 12-month target price by $15 to $510, valuing Berkshire's class B shares at 23x our 2026 operating EPS estimate of $21.80, versus their three-year average forward multiple...
Research Alert: CFRA Keeps Strong Buy Opinion On Adss Of Astrazeneca
Research Alert: CFRA Keeps Strong Buy Opinion On Adss Of Astrazeneca
Oct 13, 2025
06:20 AM EDT, 10/13/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We revised our target price to USD98 (up from USD86), which implies 19.3x our 2026 EPADS estimate, largely in line with its five-year historical forward P/E. On October 10, U.S....
Research Alert: CFRA Maintains Buy Opinion On Shares Of Jpmorgan Chase & Co.
Research Alert: CFRA Maintains Buy Opinion On Shares Of Jpmorgan Chase & Co.
Oct 14, 2025
12:20 PM EDT, 10/14/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We keep our 12-month target price at $340, applying a forward P/E of 15.5x, near the three-year historical average at 15.0x on normalized earnings. We keep our EPS estimates at...
Copyright 2023-2025 - www.financetom.com All Rights Reserved